Can't say the sales are too surprising. Levy has been there a long time and at some point deserves to cash out.
But as we talked before, the company is fully valued and has some significant risks over the next year. Baricitinib data in RA against the biologic comparator is probably the next meaningful datapoint. Not surprising to see them protect their net worth ahead of that uncertainty.
News 
Market Data 
Discover 
